Who We Are
A Scientific Institute Built on Measurable Biology
The endocannabinoid system regulates a large range of physiological processes: mood, metabolism, immune response, pain modulation, and more, yet clinical medicine has historically lacked the laboratory tools to evaluate it directly. AMCANN Research exists to close that gap. The institute draws on molecular biology, psychopharmacology, and clinical pharmacology to develop quantitative methods for detecting cannabinoid signaling in human subjects, to build a diagnostic framework held to the same evidentiary standards as those in endocrine and metabolic medicine.
Legacy
15+ Years
of groundbreaking research
Advancing Knowledge
200+ Journals
in leading scientific publications
Expertise
50+ Experts
collaborating across diverse fields
Translational Medicine Rooted in the Endocannabinoid System
Symptom-based diagnosis has its limits, and in cannabinoid medicine, those limits show up quickly. Without a biochemical reference point, there is no reliable way to distinguish a deficiency from a dysregulation, or either from normal variation. Establishing normative concentration ranges for endogenous cannabinoids in metabolically healthy individuals provides clinicians with a concrete basis to work from. This translational medicine mode, moving from laboratory data to clinical interpretation, positions cannabinoid signaling as a measurable system rather than a theoretical one. Research programs are designed not only to generate findings but to produce tools that practitioners can actually apply.
Research Impact
Diagnostic Biomarkers That Support Clinical Decision-Making
The development of reliable diagnostic biomarkers is central to everything conducted at AMCANN Research. Using high-sensitivity liquid chromatography-tandem mass spectrometry, the same analytical methodology used across clinical pharmacology and toxicology, the institute quantifies endogenous cannabinoids and related lipid signaling molecules in human plasma. Reference intervals derived from this work are intended to support objective evaluation of endocannabinoid system function, offering clinicians a biochemical basis for assessment where none has previously existed. The institute welcomes collaboration with laboratories, academic researchers, and clinicians who share an interest in advancing this area of measurement science.
Research Programs Designed for Scientific Credibility
AMCANN Research pursues its work through four integrated programs: endocannabinoid baseline mapping, endocannabinoid deficiency disorder identification, translational intervention framework development, and analytical method validation. Each program is designed to build on the last, creating a continuous investigative pipeline rather than a collection of independent studies. Findings are disseminated through peer-reviewed publications and scientific communication to researchers, clinicians, and policy stakeholders. The institute believes the endocannabinoid system merits the same methodological rigor applied to other measurable biological systems, and that the science, when done carefully, is prepared to meet that standard.
Deficiency Disorders
Every major biological system has measurable ranges—hormones, neurotransmitters, metabolic markers. The endocannabinoid system doesn’t, at least not yet. When it’s out of balance, effects show up across mood, pain, immunity, and neurological function, making issues hard to pinpoint. This program aims to change that by building the biomarker evidence needed to turn suspected deficiencies into clinical fact.
Intervention Frameworks
Knowing something is off only matters if there’s a path forward. This program asks: when you target the endocannabinoid system, does the biochemistry shift—and does it last? Through pre/post testing and longitudinal tracking, it builds the infrastructure needed to make future treatments worth trusting.
Method Development
These molecules exist in human plasma in extremely small amounts—shaping every lab decision. Sensitivity must detect them, stability must hold, and results must be reproducible. This program runs continuously to ensure the methodology stays sound, because even small drift undermines everything built on top of it.
Your questions answered
Is AMCANN Research a cannabis company?
It isn’t. The endocannabinoid system is a native biological network; present in every vertebrate, producing its own signaling compounds, regulating processes that have nothing to do with cannabis consumption. Studying it is an act of biochemistry, not advocacy. AMCANN Research is a scientific institute, and that distinction matters to everything we do.
What is the endocannabinoid system?
It’s a lipid-based signaling network your body produces and regulates on its own. It influences mood, pain, immune response, metabolism, neurological function; a surprisingly wide range of physiology for a system that doesn’t show up on a standard lab panel. That absence from routine clinical measurement is exactly what this institute exists to address.
What is Endocannabinoid Deficiency Disorder?
The working premise is straightforward: if the endocannabinoid system can fall out of normal range, and if that deviation contributes to clinical symptoms, then deficiency is a diagnosable condition; provided you have reference ranges to measure against. Those reference ranges don’t yet exist in any standardized form. Establishing them is the purpose of the flagship study.
How does AMCANN Research measure endocannabinoids?
Using LC/MS/MS; liquid chromatography-tandem mass spectrometry. It’s the same platform clinical pharmacology and forensic toxicology rely on when precision isn’t optional. Endocannabinoids appear in human plasma at very low concentrations, and the methodology has to be sensitive enough to catch them reliably. Getting that right is not a preliminary step; it runs alongside every other program the institute operates.
Does AMCANN Research work with outside collaborators?
Yes, and that’s not a formality. Establishing reference standards for a biological system this complex requires more than one institution’s data. Researchers, clinical laboratories, and practicing clinicians with relevant interests are encouraged to reach out through the Collaboration page.
How can I stay informed about AMCANN Research findings?
Published work and study updates are posted to the Publications section as they become available. For anything more direct; partnership inquiries, data questions, consultation; the contact form on the Collaboration page goes to the institute.
Get the information you need
If you didn’t find the answer you’re looking for, please reach out to us.